These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16188495)

  • 1. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program.
    Mitchell GF; Arnold JM; Dunlap ME; O'Brien TX; Marchiori G; Warner E; Granger CB; Desai SS; Pfeffer MA
    Eur J Heart Fail; 2006 Mar; 8(2):191-7. PubMed ID: 16188495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
    Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
    Ducharme A; Swedberg K; Pfeffer MA; Cohen-Solal A; Granger CB; Maggioni AP; Michelson EL; McMurray JJ; Olsson L; Rouleau JL; Young JB; Yusuf S
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of angiotensin II (AT1) receptor blockade on cardiac vagal control in heart failure.
    Vaile JC; Chowdhary S; Osman F; Ross HF; Fletcher J; Littler WA; Coote JH; Townend JN
    Clin Sci (Lond); 2001 Dec; 101(6):559-66. PubMed ID: 11724639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure.
    Kasama S; Toyama T; Sumino H; Matsumoto N; Sato Y; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
    J Nucl Med; 2007 Dec; 48(12):1993-2000. PubMed ID: 18006623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program.
    Meredith PA; Ostergren J; Anand I; Puu M; Solomon SD; Michelson EL; Olofsson B; Granger CB; Yusuf S; Swedberg K; Pfeffer MA; McMurray JJ
    J Am Coll Cardiol; 2008 Dec; 52(24):2000-7. PubMed ID: 19055992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction.
    Kasama S; Toyama T; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
    J Am Coll Cardiol; 2005 Mar; 45(5):661-7. PubMed ID: 15734608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme.
    Chang SM; Granger CB; Johansson PA; Kosolcharoen P; McMurray JJ; Michelson EL; Murray DR; Olofsson B; Pfeffer MA; Solomon SD; Swedberg K; Yusuf S; Dunlap ME;
    Eur J Heart Fail; 2010 Jul; 12(7):738-45. PubMed ID: 20418272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB
    J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency.
    Nakamura T; Kanno Y; Takenaka T; Suzuki H;
    Hypertens Res; 2005 May; 28(5):415-23. PubMed ID: 16156505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure.
    Yusuf S; Ostergren JB; Gerstein HC; Pfeffer MA; Swedberg K; Granger CB; Olofsson B; Probstfield J; McMurray JV;
    Circulation; 2005 Jul; 112(1):48-53. PubMed ID: 15983242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.
    White M; Lepage S; Lavoie J; De Denus S; Leblanc MH; Gossard D; Whittom L; Racine N; Ducharme A; Dabouz F; Rouleau JL; Touyz R
    J Card Fail; 2007 Mar; 13(2):86-94. PubMed ID: 17395047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
    Cohen-Solal A; McMurray JJ; Swedberg K; Pfeffer MA; Puu M; Solomon SD; Michelson EL; Yusuf S; Granger CB;
    Eur Heart J; 2008 Dec; 29(24):3022-8. PubMed ID: 18987098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
    Mitrovic V; Willenbrock R; Miric M; Seferovic P; Spinar J; Dabrowski M; Kiowski W; Marks DS; Alegria E; Dukát A; Lenz K; Arens HA
    Am Heart J; 2003 Mar; 145(3):E14. PubMed ID: 12660683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction.
    Tao ZW; Huang YW; Xia Q; Xu QW
    Chin Med J (Engl); 2005 Jan; 118(2):146-54. PubMed ID: 15667801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
    Yusuf S; Pfeffer MA; Swedberg K; Granger CB; Held P; McMurray JJ; Michelson EL; Olofsson B; Ostergren J;
    Lancet; 2003 Sep; 362(9386):777-81. PubMed ID: 13678871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High dose treatment with angiotensin II receptor blocker in patients with hypertension: differential effect of tissue protection versus blood pressure lowering.
    Shargorodsky M; Hass E; Boaz M; Gavish D; Zimlichman R
    Atherosclerosis; 2008 Mar; 197(1):303-10. PubMed ID: 17588581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
    McMurray JJ; Ostergren J; Swedberg K; Granger CB; Held P; Michelson EL; Olofsson B; Yusuf S; Pfeffer MA;
    Lancet; 2003 Sep; 362(9386):767-71. PubMed ID: 13678869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Olsson LG; Swedberg K; Ducharme A; Granger CB; Michelson EL; McMurray JJ; Puu M; Yusuf S; Pfeffer MA;
    J Am Coll Cardiol; 2006 May; 47(10):1997-2004. PubMed ID: 16697316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.